Objective The objective of this study was to explore the perspective of hematologists and their patients regarding the management of adult chronic immune thrombocytopenia (ITP). Methods This was a multi-center, questionnaire-based, cross-sectional study conducted between 2012 and 2013 throughout Japan. Patients Hematologists, members of the Japanese Society of Hematology in 171 institutions, and their patients were invited to participate in this study. The hematologists were mainly asked about their treatment strategies, while patients were asked about their opinion of the applied treatments, treatment effect, impact on their quality of life (QOL), and treatment satisfaction. Results Questionnaires from 204 hematologists and 213 patients were collected. One hundred sixty hematologists (78.4%) started treatment based on the patient's platelet count. Corticosteroids were considered to be the most effective treatment (44.1%). Forty-six percent of hematologists responded that treatment would be started after the platelet count fell below 20×10 9 /L with bleeding symptoms, compared to 62.9% for patients with no bleeding symptoms. A platelet count of 50×10 9 /L or lower was acceptable for 94.0% of hematologists and 66.8% of patients. Fatigue was most frequently experienced by patients (44.6%). Patients also experienced psychological symptoms (feeling of anxiety or depressive mood: 29.1%, labyrinthitis: 23.5%). While 70.6% of hematologists assumed that the patient QOL was impaired to a moderate to substantial degree, the QOL was impaired in 34.3% of patients. Conclusion A substantial gap which exists between hematologists and their patients highlights a need for better understanding of potential conflicts for establishing effective strategies for ITP management.
Introduction
Immune thrombocytopenia (ITP) is a disorder characterized by autoantibody-induced platelet destruction and impaired platelet production, leading to isolated chronic thrombocytopenia with a low peripheral blood platelet count in adult patients (1, 2) . According to an international working group (3) , if an individual is determined to have a platelet count of less than 100×10 9 /L, combined with the absence of other causes or disorders that may be associated with thrombocytopenia, he/she is diagnosed with ITP. Other causes for thrombocytopenia are comprehensively judged according to past medical history, a physical examination, a complete blood count, and an examination of a peripheral blood film (4) (5) (6) . The etiology of ITP remains unclear, although a great deal has been understood about its immunology (7) , and the physician experience in treating ITP is limited.
One of the clinical characteristics of ITP is that its symptoms may vary widely among individuals. Some patients suffer from major bleeding that requires immediate attention (8) , while others present few symptoms (7) . Severe thrombocytopenia, potentially leading to massive bleeding, may be life-threatening and require emergency therapy. At the same time, many patients have low, but not excessively low, platelet counts that may require minimal or no treatment. The treatment of ITP mainly aims at increasing the patient's platelet count to levels that are high enough to eliminate the risk of a serious hemorrhage. Although several approaches, including medical therapies and surgical interventions, have become available for the management of ITP with a recent evidence-based practice guideline (9), still there is some confusion when these different treatments should be used, or even when any treatment should be used, in place of patient management by observation alone.
Meanwhile, patients may not always understand the disease or the available treatments due to its generally mild nature. Hematologists and patients with ITP may have different perspectives regarding the management of ITP, and these differences may result in conflicting management goals. The purpose of this study was to explore the perspectives of hematologists and their patients regarding the disease and its treatment. A better understanding of potential conflicts, as well as patients' beliefs and attitudes, will assist in establishing effective strategies for adult chronic ITP management.
Materials and Methods

Study design
This was a multi-center, questionnaire-based, crosssectional study conducted between 2012 and 2013 throughout Japan. Hematologists, members of the Japanese Society of Hematology and currently treating ITP patients in 171 institutions, and their patients (aged 20 years or older) were invited to participate in this survey. Of 56 institutions which agreed to participate in this study (32.7%), a total of 204 hematologists from 51 institutions participated in this survey.
The study office distributed a questionnaire to participating hematologists, who returned the completed questionnaire to the study office by mail. As a patient sample, eligible patients who provided their written informed consent for participation received a questionnaire from a participating hematologist at their regular clinical visit. Participating patients were asked to complete the questionnaire by themselves at home and return the completed questionnaire to the study office by mail. Our goal was to obtain at least 200 completed questionnaires for both hematologists and patients, and the survey was closed on the day the number of questionnaires collected by the study office exceeded 200. To maintain independence from investigator intervention, the study office was managed by an independent organization. This study was reviewed and approved by the Ethics Committee of Juntendo University (approval number: 2012034). Written informed consent was obtained from each patient. Potential participating patients were ensured that declining to participate in the survey would place them at no disadvantage. No additional clinical interventions, examinations, or follow-up visits were required for this study. Personal identifiable information, such as names, phone numbers, and addresses, was not collected from the participating patients in order to fully protect their privacy. This study was conducted in accordance with the ethical principles of the Ethical Guidelines related to Epidemiological Research.
Survey questionnaires
The questionnaire for hematologists included items regarding the start of treatment, factors related to treatment selection, period of time necessary to provide patients with explanations regarding the disease and treatment, estimation of impact on the patient quality of life (QOL), and the efficacy and safety of the treatment options. The questionnaire for patients included questions regarding symptoms, treatments and accompanying side effects, their level of understanding regarding ITP and its treatment, treatment targets, reason not to select splenectomy, corticosteroids, source of information regarding ITP and its treatment, bleeding symptoms, concerns about ITP, and subjective perception regarding the impact on their QOL. A summary of the topics covered by the survey questionnaires is presented in Supplementary material.
Data analysis
Survey response distributions were summarized using simple descriptive statistics. Responses from 204 hematologists and 213 patients with ITP were included in the analysis. Due to the exploratory nature of this study, which aimed at collecting data in a broadly exploratory manner, a statistical power approach for determining sample size was not applied. In addition, as participating institutions were not randomly sampled, no statistical tests for the comparison between hematologist and patient responses were performed. The SAS Statistical Package, Release 9.2 (SAS, Cary, USA) was used for data analysis.
Results
Characteristics of participants
The characteristics of participating hematologists are presented in Table 1A . The mean (SD) number of participating hematologists per institution was 4.0 (2.65). Approximately 63% of them treated their patients at university hospitals. In addition, 73.5% of participating hematologists treated more than 5 patients with ITP at the time of survey, and twothirds (66.2%) reported having more than 10 years of experience in treating ITP patients.
Characteristics of participating patients are presented in Table 1B . The majority of patients were female (69.5%), and 59.2% of patients were older than 60 years of age. The duration of ITP was 10 years or more in 40.4% of patients.
The lowest experienced platelet count (/L) was less than 10× 10 9 /L in 55.4% of patients. Regarding the present platelet count, 8.9% had less than 20×10 9 /L and 60.1% had 50×10 9 / L or more. The treatments received by the patients included corticosteroids (79.8%), eradication of Helicobacter pylori (H. pylori) (44.6%), thrombopoietin-receptor agonist (TPO-RA) (24.4%), and transfusion (24.4%). Splenectomy was conducted in 17.8% of patients.
Start of treatment: timing and reasons (hematologist perspective)
Regarding the timing of starting ITP treatment, 78.4% of hematologists (n=160) initiated treatment according to the platelet count, regardless of the presence of bleeding symptoms. On the other hand, 13.7% (n=28) indicated that they do not start treatment in the absence of bleeding symptoms. Other respondents (n=16) included "both platelet count and bleeding symptoms" (n=10), and "total consideration of several factors including platelet count, age, and activities in ITP: immune thrombocytopenia daily living" (n=2). The platelet count levels used by respondent hematologists to start treatment intervention are shown in Fig. 1 . For patients with no bleeding symptoms, 37.1% would start the treatment at a platelet count more than 20×10 9 /L. This rate increased to 54.1% for patients with bleeding symptoms.
Targeted platelet counts
Both hematologist and patient perspectives regarding the target platelet count that should be achieved are presented in Table 2 . More than 90% of hematologists responded that a platelet count of 50×10 9 /L or lower was acceptable. In contrast, 67.3% of patients answered that a platelet count of 50 ×10 9 /L or higher was preferable. In addition, 26.4% of hematologists responded that 20×10 9 /L was an acceptable platelet count, although it was acceptable for only 3.8% of patients.
Effective treatments (hematologist perspective)
Corticosteroids were considered to be the most effective treatment (44.1%) by hematologists. Eradication of H. pylori was also recognized as an effective option (37.8% responded "most effective"). Splenectomy was listed as the second (27.5%) or third most effective treatment (24.5%). Rituximab, immunosuppressive agents, and platelet transfusion were considered to be relatively ineffective compared with other treatment options.
Symptoms related to ITP (patient perspective)
Patient perceived ITP-associated symptoms (not including any adverse effects associated with treatment intervention) are presented in Table 3 . Fatigue was the symptom most experienced by patients (44.6% of patients). Psychological symptoms, such as a feeling of anxiety or depressive mood (29.1%), and labyrinthitis (23.5%) were other major symptoms associated with the disease. Fig. 2 shows the proportions of patient responses regarding the impact of ITP and that of treatment on their QOL, along with hematologists' estimations of the impact on the patient QOL. As shown, a gap existed between the hematologist and patient perspectives. While 70.6% of hematologists presumed that the patient QOL was impaired to a moderate or substantial degree, only 34.3% of patients answered that their QOL was impaired to this level.
Impact on patient QOL
With regard to other questions regarding the QOL, 61.3% of patients (68/111) responded that they did not tell their attending hematologists that ITP had a negative impact on their QOL, and only 41.1% of patients (44/107) believed that their attending hematologists recognized that their QOL was affected. Regarding the effect of treatment on the patient QOL, 33.3% of patients (36/108) reported that their QOL did not improve.
Discussion
The present study is, to the best of our knowledge, the first to investigate both hematologist and patient perspectives regarding ITP and its treatment, as well as the impact on QOL, in Japan. Our results, obtained from 204 hematologists and 213 patients, revealed gaps in the perspectives between hematologists and patients.
A marked difference was found in the target platelet count between hematologists and patients: 50×10 9 /L was an acceptable platelet count level for hematologists, whereas a normal level around 100×10 9 /L was preferred by patients. The far higher platelet count targeted by patients may reflect their expectation that achieving a normal platelet count may prevent bleeding events or may alleviate symptoms greatly affecting patient life, including fatigue and psychological symptoms, to allow a normal life as healthy individuals. Other factors such as a patient's inherent character, hematologist-patient relationships, and the clinical course of a patient's ITP may influence the targeted platelet counts which patients preferred. For instance, nervous patients may feel a need to achieve higher platelet counts. Patients may also feel more anxious if their hematologist does not provide sufficient explanation about the disease, and patients who have experienced severe bleeding symptoms may feel a need to achieve higher platelet count levels. In contrast, such a high level was not considered to be required by hematologists, as a previous study reported that the majority agreed that a platelet count of 50×10 9 /L was generally sufficient in preventing patients from severe bleeding symptoms under normal activities in daily life (10) . Furthermore, hematologists set the target level lower possibly due to great concerns that excessive treatment can place psychological, physical, and economic burdens on patients. Balancing the risk of severe bleeding against the risk of side effects particularly challenges hematologists. The current condition of ITP management and our findings highlight the need to help hematologists determine the optimal target platelet level, although it is clear that the targeted platelet count should be individually tailored, taking into account factors such as the presence of bleeding symptoms, relevant activities which can lead to bleeding, or side effects of treatment.
In hematologist perceived effective treatments, Japanesespecific results were shown: the eradication of H. pylori supported by many hematologists as another effective treatment. The prevalence of H. pylori infection increases with age and is estimated to exceed 50% in the Japanese population above 50 years of age (11) . Although no association between H. pylori infection and the pathogenesis of immunemediated platelet destruction has yet been elucidated (12) , many studies have reported that eradication therapy increased the platelet counts in ITP patients (13) (14) (15) (16) (17) (18) .
ITP has a negative impact on the patient QOL (19) (20) (21) (22) , and lower platelet counts can be associated with a deterioration in the QOL (12) . The QOL of this patient group was significantly worse than that of the general population and even that of patients with other diseases, including hypertension, arthritis, and cancer (22) . However, half of the patients responded that their QOL was not affected at all in this study. Relatively preserved platelet counts (above 50×10 9 /L in more than half of the patients) and an overconcentration of patients aged 60 years or older against the usually observed bimodal age distribution (20 to 40 years and 60 to 80 years) may be attributed to the contradiction with the generally agreed-upon assumption that the QOL is greatly reduced in patients with ITP.
Another gap between hematologists and patients lies in the perception of the impact on the patient QOL; although approximately 70% of hematologists estimated that the patient QOL was affected to some degree or more, half of the patients responded that it was not affected at all. Given that more than 60% of patients did not tell their attending hematologists about a negative impact on QOL, this particular topic may not be well discussed during consultations, possibly leading to the difference. With highly variable severity, symptoms, and side effects accompanying the treatment, the therapeutic effects or strategy of treatment should be judged on symptom improvement and a patient-oriented evaluation, such as treatment satisfaction and QOL.
There are some limitations associated with this study. The selection of physicians may limit the generalizability of our results; most of them belonged to universities and relatively large hospitals. However, as most patients actually visit such institutions, our results likely reflect the standard ITP treatment in Japan. Non-randomized recruitment of patients may introduce selection bias on their demographic characteristics or perspectives regarding ITP. To reduce selection bias, the number of patients at a single site was limited, and eligible patients were consecutively invited for participation. Moreover, since the questionnaire used in this survey inquired about overall QOL, the impairment of specific QOL domains may not be inferable. Accordingly, a validated questionnaire to assess the patient QOL, preferably a diseasespecific measure, should be used to assess the patient QOL comprehensively.
The present study demonstrated a substantial gap in the target platelet counts and impact of ITP and its treatment on the patient QOL between hematologists and their patients. An increased awareness of the presence of differing opinions regarding ITP treatment may improve management decisions.
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